Register now for SmartTRAK's "The State of the Spine Market" webinar to be held on Wednesday, September 22, 2021 at 1:00 pm ET. Learn from SmartTRAK's General Manager of Spine, Julianne Burns, about the latest trends in the Spine market and how COVID-19 continues to impact the market. 

Agenda:

• A Look Back: How COVID Impacted the Spine Market in Q1 & Q2
• Q3 and Beyond: Dealing with Delta and More
• Market Drivers & Trends
• Q&A

Registration is free but limited. Sign up now to reserve your spot!

Julianne Burns, Smarttrak's General Manager, Spine, has 15+ years' experience in consulting, market development and marketing in the spine industry, including 7+ years at Medtronic Spinal & Biologics.

After another difficult year, it's time to get out there and start reconnecting in person. SmartTRAK is excited to be traveling to Charlotte, NC to attend AOFAS at the Charlotte Convention Center, September 21-25.

SmartTRAK will be represented by Natasha Weeks, General Manager, Trauma & Extremities. Natasha is also managing our 3 newest modules, Pediatric Trauma, Pediatric Extremities and Pediatric Spine. If you would like to meet with Natasha while attending the meeting, just click here.

Now that we're back to in-person meetings, it's time to resume our continuing series Know Before You Go, so I sat down and asked Natasha a few questions about what she is looking forward to at AOFAS.

We are excited to announce the addition of the full market view of Orthopedic Pediatrics (US) to the SmartTRAK platform, featuring 3 modules covering Pediatric Trauma, Pediatric Extremities and Pediatric Spine!

Natasha Weeks, General Manager, Trauma & Extremities, will be managing Pediatric Trauma & Extremities and the Spine module will be managed by Julianne Burns, General Manager, Spine.

In the following video, Lindsey Wolejko, SmartTRAK's Director of Marketing, discusses with Natasha and Julianne what's included in each new module and why we're so excited about these additions to the SmartTRAK platform. To request more information about these offerings, please click here.

Procedures using surgical matrices rebounded to normal levels again, with broad strength in both hernia and breast matrices.

Procedures using surgical matrices returned to approximately normal levels, though the Delta variant may make that recovery short-lived, as recently observed in Texas. The US Surgical Matrices market rebounded strongly in Q221 according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* continued to lead the US Surgical Matrices market, with Becton Dickinson* (BD) bouncing back nearly as strongly.

Among the many topics covered in detail in our comprehensive Q221 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants came roaring back from its pandemic depths in Q221 as procedures returned to normal.  

As surgical procedures returned to approximately normal levels, the US Hemostats and Sealants market grew +51.1% YoY in Q221 according to SmartTRAK Financial Dashboard. Growth was strong across all segments and companies. However, the Delta variant may make that recovery short-lived, as recently observed in Texas.

Among the many topics covered in detail in our comprehensive Q221 US Hemostats and Sealants Market Recap* are:

Brett Wall, EVP and President of Medtronic’s Neuroscience Portfolio, discusses changes and opportunities in the Neuroscience business in an interview with SmartTRAK. 

Brett Wall, EVP and President of Medtronic’s Neuroscience Portfolio, discusses how things are changing at Medtronic, his plans for the Neuroscience business and opportunities for growth in an interview with SmartTRAK. To find out more, including Wall’s vision for spine, neuromodulation and neurovascular, click on the following video. (25:58 min). A link to download a complete transcript of the interview is also provided below.

Easily accessible from your computer, tablet or smartphone, SmartTRAK is the most comprehensive business intelligence platform for the MedTech industry. SmartTRAK's real-time data allows everyone in your organization to tap into the same data to drive strategic consistency and increase collaboration across your enterprise. Need help with your roadmap? Watch the video below to learn how SmartTRAK can help.

Planning to go to AAOS? Meet with us in San Diego to learn more about what's coming down the road, including:

Q221 brought mixed reviews for Total Joints as Hips exceed pre-COVID levels and Knees fall flat

The Total Joints market accelerated sequentially with a return of patients and procedural volume growth in the quarter. However, compared to 2019, results varied by segment, The Hip Replacement segment put in the best performance with the US Hip Market in Q221 compared to pre-COVID’s Q219 levels. US Knees did not experience the same level of success as revenues were down.

Among the many topics covered in detail in our comprehensive Q221 Total Joints Market Recap* are:

• Complete Q221 Total Joints Market Overview and Highlights
• SmartTRAK's Expert Analysis and Insights
• Total Joints News including Revenues, Data, Charts and Shares
• US Market Growth Comparison Q221 vs Q219
• Acquisitions, Deals & Financing News
• New Products Hitting the Stage
• Q221 Regulatory Highlights 

SNIS President William J. Mack, MD discusses trends and technologies in stroke care in an interview with SmartTRAK

William J. Mack, MD, President of the Society of Neurointerventional Surgery (SNIS), provides insight into trends and technologies in stroke care in an interview with SmartTRAK at the SNIS 18 ^th  Annual Meeting in Colorado Springs held July 26-30, 2021. Key topics include: 

• Advancing the stroke systems of care
• Trends in practice and device use for acute ischemic stroke
• Risks, benefits and challenges of treating more distal strokes
• Promising technologies on the horizon, including robotics
• Impact of COVID resurgence on clinical practice

To get the latest on stroke care, click on the following video to listen to a fascinating interview recorded live at SNIS (13:08). A link to download a transcript of the complete interview is also provided below.

Declining COVID cases, M&A and new products fueled the race to recovery in the Extremities Market

As COVID cases declined in Q221 and patient confidence increased, the Extremities Market was off to the races with a rev-up in deal-making and new product launches. Elective procedure volumes started to make a comeback but were not pedal to the metal and still lagged pre-COVID levels. However, new product launches helped fuel growth in the quarter with the US Extremities Market +43.9% YoY, an increase of +8.2% compared to Q219, reflecting change over pre-COVID market conditions. 

Among the many topics covered in detail in our comprehensive Q221 Extremities Market Recap* are: